Pfizer Inc. (NYSE:PFE) Shares Bought by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. grew its position in Pfizer Inc. (NYSE:PFE) by 4.7% in the fourth quarter, HoldingsChannel reports. The fund owned 129,407 shares of the biopharmaceutical company’s stock after acquiring an additional 5,859 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Pfizer were worth $3,726,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of PFE. Wedge Capital Management L L P NC raised its position in shares of Pfizer by 10.6% in the third quarter. Wedge Capital Management L L P NC now owns 10,865 shares of the biopharmaceutical company’s stock worth $360,000 after acquiring an additional 1,044 shares during the period. Essex LLC increased its stake in shares of Pfizer by 16.4% during the third quarter. Essex LLC now owns 66,014 shares of the biopharmaceutical company’s stock worth $2,190,000 after purchasing an additional 9,288 shares in the last quarter. Capital Investment Advisors LLC increased its stake in shares of Pfizer by 5.9% during the third quarter. Capital Investment Advisors LLC now owns 718,558 shares of the biopharmaceutical company’s stock worth $23,835,000 after purchasing an additional 40,233 shares in the last quarter. Guidance Capital Inc. increased its stake in shares of Pfizer by 9.9% during the third quarter. Guidance Capital Inc. now owns 15,080 shares of the biopharmaceutical company’s stock worth $511,000 after purchasing an additional 1,358 shares in the last quarter. Finally, Onyx Bridge Wealth Group LLC increased its stake in shares of Pfizer by 12.1% during the third quarter. Onyx Bridge Wealth Group LLC now owns 17,201 shares of the biopharmaceutical company’s stock worth $571,000 after purchasing an additional 1,852 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.2 %

NYSE:PFE traded down $0.06 on Wednesday, hitting $26.26. The stock had a trading volume of 24,501,011 shares, compared to its average volume of 41,887,898. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a market cap of $148.70 billion, a price-to-earnings ratio of 72.94, a PEG ratio of 1.18 and a beta of 0.61. The company has a fifty day moving average price of $27.05 and a two-hundred day moving average price of $28.50. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the previous year, the business posted $1.14 EPS. Pfizer’s revenue was down 41.3% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.40%. Pfizer’s dividend payout ratio is currently 466.67%.

Analyst Ratings Changes

A number of research firms have recently commented on PFE. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.